SCHEDULE: Tango Therapeutics: Invus Group Discloses Stake

Invus Group entities and Raymond Debbane have collectively reported beneficial ownership of 5,657,105 shares, representing 4.0% of Tango Therapeutics' common stock as of March 31, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Tango Therapeutics, Inc. common stock.
• Several entities associated with Invus Group, including Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, and Siren, L.L.C., collectively hold 4,964,650 shares.
• Additionally, Avicenna Life Sci Master Fund LP and its general partner Avicenna Life Sci Master GP LLC, along with Ulys, L.L.C., hold 692,455 shares.
• Raymond Debbane, associated with all these entities, is reported to beneficially own a total of 5,657,105 shares.
• As of March 31, 2026, this collective ownership represents 4.0% of Tango Therapeutics' outstanding common stock.
• The filing states that these securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership and does not provide new operational or financial information about Tango Therapeutics, Inc.

Positives

• Significant stake held by Invus Group and Raymond Debbane, indicating investor confidence or strategic interest.
• Clear disclosure of beneficial ownership, adhering to regulatory requirements.

Risks

• The filing does not detail specific business operations or financial performance of Tango Therapeutics, Inc., limiting the assessment of inherent business risks.
• Potential for future changes in beneficial ownership, which could impact stock price and corporate control.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Tango Therapeutics, Inc.'s future performance. It solely reports on beneficial ownership.

Management Comments

• Each of the Reporting Persons hereby makes the following certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders to report their holdings. This filing indicates a substantial investment in Tango Therapeutics by entities associated with the Invus Group, suggesting a strategic interest in the biotechnology sector, specifically within Tango's focus areas.

Stakeholder Impact

• Shareholders: The filing confirms a significant stake held by Invus Group and Raymond Debbane, which may influence market perception and potential future corporate actions.
• Management: The certification regarding control indicates that the reporting persons are not currently seeking to influence control of Tango Therapeutics, Inc.

Next Steps

• Continued monitoring of Tango Therapeutics, Inc. for future disclosures or operational updates from the company.
• Potential for further filings from Invus Group or Raymond Debbane if their ownership stake changes significantly.

Key Dates

Keywords

Tango Therapeutics, Schedule 13G, SEC Filing, Beneficial Ownership, Invus Group, Raymond Debbane, Common Stock, Investment, Securities Exchange Act